 Relmada Therapeutics Inc NASDAQ: RLMD has acquired the development and commercial rights to novel psilocybin and derivate program from Arbormentis LLC in all ex-Asia territories, including the U.S. and Europe. Relmada will collaborate with Arbormentis to develop new therapies targeting neurological and psychiatric disorders. 